Sana Biotechnology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance as of December 31, 2025 | 266,732 | $27 | $2,009,845 | $28 | $(1,849,016) | $160,884 |
| Fees incurred related to common stock financings | - | - | (125) | - | - | (125) |
| Exercise of pre-funded warrants | 2,192 | - | - | - | - | - |
| Vesting of restricted stock | 864 | - | - | - | - | - |
| Exercise of stock options | 29 | - | 59 | - | - | 59 |
| Stock-based compensation expense | - | - | 5,662 | - | - | 5,662 |
| Unrealized loss on marketable securities, net | - | - | - | (30) | - | (30) |
| Net loss | - | - | - | - | (47,210) | (47,210) |
| Balance as of March 31, 2026 | 269,817 | $27 | $2,015,441 | $(2) | $(1,896,226) | $119,240 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders' | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Loss · Deficit · Equity | |||||||
| Balance as of December 31, 2024 | 223,923 | $22 | $1,855,318 | $14 | $(1,604,850) | $250,504 | |
| Fees incurred related to common stock financings | - | - | (171) | - | - | (171) | |
| Vesting of restricted stock | 960 | - | - | - | - | - | |
| Exercise of stock options | 580 | 1 | 1,126 | - | - | 1,127 | |
| Stock-based compensation expense | - | - | 7,022 | - | - | 7,022 | |
| Unrealized loss on marketable securities, net | - | - | - | (14) | - | (14) | |
| Net loss | - | - | - | - | (49,389) | (49,389) | |
| Balance as of March 31, 2025 | 225,463 | $23 | $1,863,295 | $ | - | $(1,654,239) | $209,079 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.